###### Strengths and limitations of this study

-   This study used the PROVAR+ (*Programa de RastreamentO da VAlvopatia Reumática*) cohort, the first large prospective cohort of schoolchildren with latent rheumatic heart disease (RHD) in Brazil.

-   This is the first validation study of a previously published (2019) scoring system to discriminate children found to have early echocardiography evidence of RHD into those who are likely to have favourable versus unfavourable outcomes.

-   Echocardiograms were interpreted by the consensus of two experts with high familiarity in the World Heart Federation criteria.

-   As this was an established cohort, no predefined sample size was calculated for this study and all screen-positive patients were invited for follow-up.

-   A passive recruitment strategy meant that there was low overall participation; only 36% of screen-positive children were enrolled in the follow-up programme, reducing the size of the potential cohort.

Introduction {#s1}
============

Rheumatic heart disease (RHD) is the major cause of acquired cardiovascular disease in children and young adults worldwide. Its global burden is noteworthy, affecting 39 million people and causing 319 400 deaths annually.[@R1] The disease is more prevalent in low-income and middle-income countries, where it is typically diagnosed only once advanced valve disease is present and symptoms develop.[@R1] However, there is a latent period, often up to a decade, between the first episode of acute rheumatic fever (ARF) and advanced RHD, when early identification can improve outcomes.

In this context, echocardiographic (echo) screening in endemic areas has emerged as an effective approach to identify patients who are in this latent, subclinical stage of RHD.[@R3] Diagnostic criteria for subclinical RHD---asymptomatic patients with echo findings suggestive of RHD without a history of ARF---have been standardised by the World Heart Federation (WHF) consensus in 2012. Three categories are defined: definite, borderline and normal.[@R7] The morphological findings of RHD and the criteria for pathologic valve regurgitation are also established. This standardisation has allowed for comparison between studies carried out in different populations.

Although criteria are standardised, prognosis and natural history of latent RHD, and the impact of clinical interventions---such as secondary prophylaxis---still require further evaluation. The first studies that evaluated the follow-up of patients with subclinical RHD have several limitations, including relatively short follow-up times, small sample size and lack of standardised criteria for echo and clinical progression.[@R8] However, data suggest that RHD progression in children with latent RHD is not negligible.[@R9] Therefore, we aimed to assess the mid-term evolution of Brazilian schoolchildren (5--18 years) with subclinical RHD findings observed in echo screening[@R4] and to assess the performance of a simplified score developed by Nunes *et al,*[@R9] consisting of five components of the WHF criteria, as a predictor of unfavourable echo outcomes.

Methods {#s2}
=======

This is a prospective cohort study with systematic clinical and echo follow-up of children with subclinical RHD. It was derived from a RHD screening programme, stablished in Brazil in 2014---the PROVAR+ (*Programa de RastreamentO da VAlvopatia Reumática*) study---a collaboration between the Children's National Health System, Washington, DC, USA, the Universidade Federal de Minas Gerais (UFMG) and the Telehealth Network of Minas Gerais,^[@R11]^ Belo Horizonte, Minas Gerais, Brazil. This screening programme has already screened more than 12 000 children and adolescents from 21 schools in Minas Gerais, Brazil, between October 2014 and December 2016.[@R4]

In brief, public schools and primary care centres from low-income areas of metropolitan Belo Horizonte, Brazil, were selected to participate in the screening programme, based on socioeconomic data (Human Development Index (HDI)) and priorities of the health authorities. Two selected private schools were also invited in order to characterise RHD in high-income youth. All asymptomatic students, without a history of ARF or RHD, were eligible for screening.[@R4] All participants were informed about the study and had informed consent signed by their parents or by themselves, if of legal age.

The echo screening was performed from 2014 to 2016 by previously trained non-physicians (nurses and imaging technicians) and images were uploaded to a dedicated cloud storage system and interpreted through telemedicine by cardiologists in Brazil and the USA,[@R12] applying the WHF criteria. Detailed screening methodology has been previously published.[@R4]

Participants with abnormal screening were invited for the UFMG Pediatric Cardiology outpatient clinics and were prospectively enrolled. All patients included in the follow-up from Belo Horizonte had the baseline screening diagnosis confirmed by standard echocardiography, scheduled in the University Hospital. The ones from Montes Claros had the diagnosis based on consensus reads of GE VSCAN handheld studies. Specific care of these patients was left to the discretion of the caring cardiologist with experience in RHD. Families received phone reminders of the follow-up visits and, when necessary, study correspondence by mail. The prespecified 24-month follow-up consisted of a clinical appointment by a paediatrician (BMB and ACD), with standardised clinical history (demographics, comorbidities, cardiovascular symptoms, recurrence of pharyngitis, medications and adherence to prophylaxis---when indicated) and detailed physical examination forms, and standard echocardiogram by an experienced paediatric cardiologist (SDR) (Vivid IQ, GE Healthcare, Milwaukee, Wisconsin, USA), blinded to the findings of the previous examination and based on the WHF criteria. A standardised imaging protocol was applied. Patients were then reclassified by consensus with adjudication by two experts (MCPN and ZMAM) in the four pre-established categories. Specific care of these patients and indication for secondary prophylaxis---not mandatory for any category---were left to the discretion of the caring cardiologist (ZMAM, SRTC and MCPN). All echo and clinical variables were systematically collected in a dedicated online database.

The simplified echo score proposed by Nunes *et al*, consisting of five variables (mitral valve anterior leaflet thickening, excessive leaflet tip motion, regurgitation jet length ≥2 cm and aortic valve focal thickening and any regurgitation)[@R9] was applied to this population. An unfavourable outcome was defined as worsening in diagnostic category (borderline to definite), remaining with mild definite RHD or worsening in the grade of mitral or aortic valve regurgitation or development/worsening grade of mitral stenosis. A favourable outcome was defined as disease regression---considered when an improvement in diagnostic category was observed or in case of reduction of regurgitation severity---or remaining with stable borderline RHD.

Patient and public involvement {#s2-1}
------------------------------

Patients and public were not involved in the design and conduct of this research.

Data analysis and statistics {#s2-2}
----------------------------

Data were systematically entered into the RedCap online database.[@R13] Statistical analysis was performed using SPSS software V.23.0 for Mac OSX (SPSS). As we used a pre-existing cohort, no prespecified sample size calculation was performed, and we considered the total sample of asymptomatic schoolchildren enrolled in the 26-month screening. All screen-positive children who attended the follow-up visit were included in this analysis. Continuous variables were expressed as mean ± SD or as median and IQR, (Q1/Q3) when appropriate. Categorical variables were expressed as absolute values ​​and percentages. The between-group comparison (progression vs regression/stable) was performed using the Fisher's Exact Test for categorical variables.

The simplified echo score[@R9] was applied to this population of schoolchildren to assess its discrimination and calibration in predicting unfavourable outcome using logistic regression. The predictive value of the score was assessed as a time-dependent variable in the Cox proportional hazards model. RHD favourable outcome rates of the three risk categories (low/intermediate/high), based on the hazard of evolving with unfavourable echo outcome, were estimated by the Kaplan-Meier method and compared by the log-rank test. A two-tailed significance level of 0.05 was considered statistically significant.

Results {#s3}
=======

A total of 197 patients were included, being 114 (36%) out of 317 children with positive screening echos in Belo Horizonte and 83 (37%) of 224 in Montes Claros, with a mean 29±9 (range 11--48) months follow-up, considering the latest clinical visit. At baseline, 170 (86.3%) had borderline and 27 (13.7%) had definite RHD. Median age was 14.1 (IQR 12.0--16.2) years, and 130 (66%) were woman. Belo Horizonte and Montes Claros had similar rates of borderline (85.1% vs 88.0%) and definite (14.9% vs 12.0%) RHD at baseline (p=0.56). Only 13 (6.6%) patients, 4 of whom originally classified as definite RHD, were regularly receiving penicillin (7 with \<80% adherence). Detailed baseline demographic and echo characteristics are depicted in [table 1](#T1){ref-type="table"}. Compared with the 344 patients without follow-up, the study sample had similar baseline distribution of borderline/definite diagnoses (86.3%/13.7% vs 89.5%/10.5%, p=0.26) as well as WHF subgroups for borderline (p=0.27) and definite (p=0.10) RHD, HDI (0.77 (IQR 0.76--0.80) vs 0.77 (IQR 0.76--0.80), p=0.22), household (4 (IQR 4--5) vs 4 (IQR 4--6) inhabitants, p=0.25) and age (14.2 (IQR 12.0--16.2) vs 14.1 (IQR 11.8--15.8) years, p=0.46), but a slightly higher proportion of women (66.3% vs 57.0%, p=0.03) was observed.

###### 

Baseline characteristics of patients with borderline and definite rheumatic heart disease

  Variable                                                                              Result
  ------------------------------------------------------------------------------------- ---------------
  Borderline RHD (N=170)                                                                
  Age (years), median (IQR)                                                             14 (11--16)
  Female gender, N (%)                                                                  111 (65.7)
  Follow-up period (months), mean±SD                                                    28.9 ± 9.0
   At least two morphological features of RHD of the MV without pathological MR or MS   5 (2.9)
   Pathological MR                                                                      135 (79.4)
   Pathological AR                                                                      30 (17.6)
  Definite RHD (N=27)                                                                   
  Age (years), median (IQR)                                                             14.0 (12--16)
  Female gender, N (%)                                                                  19 (70.4)
  Follow-up period (months), mean±SD                                                    29.5±9.2
   Pathological MR and at least two morphological features of RHD of the MV             24 (88.9)
   MS mean gradient ≥4 mm Hg                                                            0
   Pathological AR and at least two morphological features of RHD of the AV             0
   Borderline disease of both the AV and MV                                             3 (11.1)

AR, aortic regurgitation; AV, aortic valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; RHD, rheumatic heart disease.

Cardiovascular symptoms were reported by 69 (35%) patients in the follow-up visits, including dyspnoea (15.2%) and palpitations (14.2%). However, clinical evaluation, physical examination and echocardiograms did not support a cardiac aetiology of these symptoms. During the follow-up, at least one episode of pharyngitis was reported by 92 patients, with 62 (67%) adequately treated in primary care, as informed by patients or parents.

Among patients with borderline RHD, 29 (17.1%) progressed to definite RHD, 49 (28.8%) remained stable, 86 (50.6%) regressed to normal and 6 (3.5%) were reclassified as other heart diseases. Among those with definite RHD, 13 (48.1%) remained in the category, while 5 (18.5%) regressed to borderline, 5 (18.5%) regressed to normal and 4 (14.8%) were reclassified as other heart diseases ([figure 1](#F1){ref-type="fig"}). No patients had worsening grade of mitral or aortic regurgitation or development/worsening grade of mitral stenosis.

![RHD progression during the follow-up according to the diagnosis at baseline. RHD, rheumatic heart disease.](bmjopen-2020-036827f01){#F1}

Among borderline patients who progressed, 26 (89.7%) had mitral regurgitation, 2 had aortic regurgitation and 14 (48.3%) had at least one morphological abnormality of the mitral valve as the initial criteria. At follow-up, 12 patients developed morphological abnormalities of the mitral (N=10) and aortic (N=4) valves. No patients developed ventricular dysfunction or enlargement ([table 2](#T2){ref-type="table"}).

###### 

Baseline echocardiographic variables of patients with progression, stabilisation and regression of rheumatic heart disease at 2-year follow-up

  Valve                               Variable\*                           Progressed: borderline to definite (N=29)   Remained definite (N=11)   Regressed/stable (borderline)/other (N=156)
  ----------------------------------- ------------------------------------ ------------------------------------------- -------------------------- ---------------------------------------------
  Mitral valve, N (%)                 Anterior leaflet thickening†         18 (62.1)                                   10 (90.9)                  103 (65.6)
                                      Chordal thickening                   0                                           2 (18.2)                   0
                                      Restricted leaflet motion            1 (3.4)                                     4 (36.4)                   4 (2.5)
                                      Excessive leaflet tip motion         2 (6.9)                                     6 (54.5)                   20 (12.7)
                                      Mitral stenosis                      0                                           0                          0
                                      Any regurgitation                    28 (96.6)                                   11 (100)                   141 (90.4)
                                      Regurgitation seen in two views      26 (89.7)                                   10 (90.9)                  141 (90.4)
                                      Jet length ≥2 cm‡                    25 (86.2)                                   9 (81.8)                   116 (74.4)
  Velocity ≥3 m/s for one envelope§   9 (31.0)                             4 (36.4)                                    32 (20.5)                  
                                      Pansystolic jet (colour Doppler)     15 (51.7)                                   8 (72.7)                   99 (63.5)
  Aortic valve, N (%)                 Irregular or focal thickening        0                                           2 (18.2)                   1 (0.6)
  Coaptation defect                   0                                    1 (9.1)                                     2 (1.3)                    
                                      Restricted leaflet motion            0                                           0                          0
                                      Leaflet prolapse                     0                                           0                          0
                                      Any regurgitation                    2 (6.9)                                     3 (27.3)                   32 (20.5)
                                      Regurgitation seen in two views      2 (6.9)                                     2 (18.2)                   28 (17.9)
                                      Jet length ≥1 cm‡                    1 (3.5)                                     3 (27.3)                   29 (18.6)
                                      Velocity ≥3 m/s in early diastole§   0                                           1 (9.1)                    6 (3.9)
                                      Pandiastolic jet (colour Doppler)    0                                           2 (18.2)                   20 (12.8)

\*\* Congenital mitral valve or aortic valve abnormalities were excluded.

† Abnormal thickening of the anterior mitral valve leaflet ≥3 or \>4 mm using harmonic imaging.

‡ In at least 1 view.

§ Measurements available with the Vivid-Q exams.

Predictive performance of the simplified echocardiographic score {#s3-1}
----------------------------------------------------------------

The simplified score, based on components of the WHF criteria, was a significant predictor of RHD unfavourable outcome (HR 1.197, 95% CI 1.098 to 1.305, p\<0.001). The discrimination of the score was good (C-statistic=0.714, 95% CI 0.627 to 0.801), and the model was well calibrated ([online supplementary appendix figure 1](#SP1){ref-type="supplementary-material"}). A Hosmer-Lemeshow p=0.589 confirmed no significant difference between observed and predicted unfavourable outcome ([online supplementary appendix figure 2A, B](#SP2){ref-type="supplementary-material"}).
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The score classified 121 children in low-risk, 48 in the intermediate-risk and 28 in the high-risk groups. Additionally, the score model was able to separate low-risk, intermediate-risk and high-risk categories for unfavourable disease outcomes ([figure 2](#F2){ref-type="fig"}). Favourable RHD outcome risk rate in the low-risk children at 1-year and 2-year follow-up was 99% and 97%, respectively, compared with 76% and 47% in the high-risk group.

![Cumulative incidence of disease unfavourable outcomes in children with echocardiography-detected RHD according to risk categories of the simplified score. RHD, rheumatic heart disease.](bmjopen-2020-036827f02){#F2}

Discussion {#s4}
==========

In agreement with the growing international data,[@R8] subclinical RHD in Brazil has a variable outcome. Approximately one in five children with borderline RHD progressed to definite RHD and more than one in three children with definite RHD remained in this category. A recently developed risk stratification score[@R9] was a modest, but significant, predictor of unfavourable echo outcome in our population.

Since its inception, the PROVAR+ research programme has been studying the use of echocardiography to improve the early detection of RHD[@R12] in Brazil. Epidemiological characterisation of RHD prevalence, and study of portable and handheld devices, task-shifting and telemedicine have been undertaken to understand how to improve diagnostic access in low-resource populations.[@R4] Determining outcomes for children with subclinical RHD is a critical next step to inform programme evaluation, as for other screening programmes worldwide. These data, with a mean follow-up of 29 months, show that both borderline and definite RHD are dynamic phenotypes, with borderline RHD showing more favourable outcomes.[@R6]

Nearly half (46%) of the youth in this programme improved echocardiographically to normal, similar to global rates ranging from 47% to 67%.[@R8] Yet borderline RHD was not a benign finding, with one in five (17%) of children progressing to definite RHD, in line with global data, which have reported 17%--23% progression at 2.5--7.5 years of follow-up.[@R8] Children with definite RHD at diagnosis had more unfavourable outcomes with 40% remaining definite, though no child progressed to moderate or severe RHD, reflecting a mildly phenotype in screen-detected RHD in Brazilian youth compared with the global data.[@R8] This milder phenotype may reflect the relatively stronger public health system in Brazil, compared with many other RHD-endemic areas, facilitating higher rates of sore throat and rheumatic fever diagnoses, but more data are needed. The impact of secondary prophylaxis in this cohort cannot be determined, as few were prescribed prophylaxis and adherence was not well captured, and we await the results of a large randomised clinical trial on the impact of penicillin prophylaxis in screen-detected youth, currently ongoing in Uganda (*Gwoko Adunu pa Lutino* (GOAL); clinicaltrials.gov No. NCT03346525).

The most novel aspect of this follow-up study was the application of a newly developed score to predict unfavourable outcome among children with screen-detected RHD.[@R9] Addressing the need to simplify the WHF criteria and improve the applicability for use with handheld echocardiography (lacking spectral Doppler), Nunes *et al* developed a five-component point-based score that showed considerable accuracy for predicting disease progression in two large African cohorts.[@R9] The score showed modest discrimination for unfavourable outcome in our population, potentially related to the less aggressive RHD phenotype in Brazil as compared with African cohorts,[@R8] suggesting wider external validation and recalibration may be necessary for global application. However, still in a population with a relatively low risk of progression---especially to clinically significant disease---its discrimination of subgroups at higher risk of unfavourable echo outcome points towards a useful public health tool and urges further investigations.

The PROVAR+ programme has encountered several context-specific limitations and lessons learnt. First, the programme has struggled with low-participation and high attrition compared with other global populations: only 40% of students have consented to school-based screening[@R5] and only 36% of screen-positive children from the schools were enrolled in follow-up. Consequently, the sample size was limited---although comparable with other RHD follow-up studies---and may preclude more definite conclusions. Much higher participation rates were seen in primary healthcare screening (84.4%,[@R5] suggesting this location is more appropriate in our context. Second, in the absence of a gold standard, prescription of penicillin for secondary prophylaxis was left to the discretion of the treating physician. Low rates of prescription were seen compared with those reported globally, suggesting the need for widespread provider education based on the results from the GOAL (*Gwoko Adunu pa Lutino*; clinicaltrials.gov No. NCT03346525) study. Finally, no child progressed to clinically significant RHD, suggesting the timeline of progression may be longer in the Brazilian context and not adequately captured by the relatively short follow-up interval. This may have important implications on when to screen and cost-effectiveness evaluations. Despite these limitations, the PROVAR+ programme is the only longitudinal programme evaluating the impact of echoscreening in Latin America.

Conclusion {#s5}
==========

These data suggest that screen-detected RHD in Brazil is not benign; patients with definite RHD are likely to remain in this category, and progression rates of borderline RHD are not negligible. The simplified echocardiography score[@R9] assessed in an independent population with predominantly low risk for RHD progression was accurate to predict early unfavourable outcome. Additional investigations are needed to establish the long-term prognosis of subclinical RHD and the effects of prophylaxis in high-risk subgroups.
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